Norway· NO-ID_4012BF3E-40A9-4873-B943-3E4C841ED816
Imjudo
A tremelimumab product containing tremelimumab, registered in Norway by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Tremelimumab is registered in 16 of 19 countries.
Countries holding a registration under ATC L01FX20 (tremelimumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Tremelimumab · ATC L01FX20
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tremelimumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tremelimumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$779.98
The record
At a glance
FEST (Norway)- Active substance
- Tremelimumab
- Manufacturer
- AstraZeneca AB
- Country
- Norway (NO)
- ATC code
- L01FX20
- ATC class
- Tremelimumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_4012BF3E-40A9-4873-B943-3E4C841ED816
- no_varenummer0859411 x 15NOK 208874.8
- no_varenummer1028881 x 1.25NOK 22834.5
- gtin5000456037204
- gtin5000456037044
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tremelimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumImjudo 20 mg/mlAstraZeneca
- CzechiaIMJUDOAstraZeneca AB, Södertälje
- FinlandIMJUDOAstraZeneca AB
- SwedenIMJUDO 20 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- IrelandIMJUDO 20 mg/ml concentrate for solution for infusionAstraZeneca AB
- IcelandImjudoAstraZeneca AB*
- PolandImjudoAstraZeneca AB
- United StatesIMJUDOAstraZeneca Pharmaceuticals LP
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imjudo
- Liechtenstein · Imjudo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b7453f7f-7f25-4694-83d6-fcefef78e57d GET /v1/drugs/b7453f7f-7f25-4694-83d6-fcefef78e57d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Tremelimumab",
"merkevare_id": "ID_4012BF3E-40A9-4873-B943-3E4C841ED816",
"name_form_strength": "Imjudo kons til inf oppl 20 mg/ml",
"prescription_group": "C"
}See everything about tremelimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.